Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.73 |
| ▸ | CDK1 | P06493 | 7/20 | 0.73 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | PRKACG | P22612 | 1/20 | 0.43 |
| ▸ | PRKACB | P22694 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019514 | 0.87 | CDK1 (0.55) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL19618131 | 0.87 | CDK1 (0.55) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL29611365 | 0.84 | CDK1 (1.00) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL756644 | 0.84 | CDK1 (1.00) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL233134 | 0.84 | ADORA2A (0.64) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL179391 | 0.84 | CDK1 (0.53) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL179417 | 0.84 | CDK1 (0.53) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL233129 | 0.84 | ADORA2A (0.64) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL179433 | 0.84 | CDK1 (0.53) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL27408120 | 0.84 | CDK1 (0.53) | CDK2CDK1CCNE1CCNB1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | VERTEX PHARMACEUTICALS INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130137650-A1 | METHODS OF TREATMENT USING COMBINATION THERAPY | AMBIT BIOSCIENCES CORP. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8357690-B2 | Methods of treatment using combination therapy | AMBIT BIOSCIENCES CORPORATION (US) | 2013-01-22 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100292177-A1 | Methods of treatment using combination therapy | AMBIT BIOSCIENCES CORP. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | CDK2 4868/4885CDK1 4739/4885CCNE1 4880/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CDK2 1244/4885CDK1 428/4885CCNE1 2247/4885 |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | GALK1, PHKA1, PGK1 | CDK2 598/4885CDK1 231/4885CCNE1 920/4885 |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | CDK2 2563/4885CDK1 2513/4885CCNE1 2113/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | CDK2 4128/4885CDK1 2855/4885CCNE1 3658/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CDK2 595/4885CDK1 1126/4885CCNE1 3249/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | CDK2 1492/4885CDK1 1837/4885CCNE1 3058/4885 |
| US-11801255-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, GSTO1 | CDK2 2495/4885CDK1 2497/4885CCNE1 2032/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | CDK2 4868/4885CDK1 4739/4885CCNE1 4880/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | CDK2 1492/4885CDK1 1837/4885CCNE1 3058/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | CDK2 3025/4885CDK1 2787/4885CCNE1 3531/4885 |
| US-20100292177-A1 | Methods of treatment using combination therapy | TOP2A, TOP2B, TOP1 | CDK2 451/4885CDK1 411/4885CCNE1 647/4885 |
| US-20130137650-A1 | METHODS OF TREATMENT USING COMBINATION THERAPY | TOP2A, TOP2B, TOP1 | CDK2 451/4885CDK1 411/4885CCNE1 647/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | CDK2 1128/4885CDK1 1860/4885CCNE1 2845/4885 |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | TYMP, POLN, POLRMT | CDK2 2438/4885CDK1 2679/4885CCNE1 3201/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | CDK2 2286/4885CDK1 2336/4885CCNE1 3606/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CDK2 3886/4885CDK1 1548/4885CCNE1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.